galidesivir   Click here for help

GtoPdb Ligand ID: 11920

Synonyms: BCX-4430 | BCX4430 | Immucillin-A
PDB Ligand
Compound class: Synthetic organic
Comment: Galidesivir (BCX4430) is an adenosine analogue and broad-spectrum antiviral agent [3]. It was originally developed as a treatment for hepatitis C infection, but has subsequently demonstrated activity against Ebola, Marburg and Zika [1] viruses, and was most recently evaluated for potential to treat SARS-CoV-2 infection (COVID-19). Mechanistically it inhibits the virus' RNA-dependent RNA-polymerase (RdRp), that acts as a nonobligate RNA chain terminator.
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 7
Hydrogen bond donors 6
Rotatable bonds 2
Topological polar surface area 140.31
Molecular weight 265.12
XLogP -1.06
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES OC[C@H]1N[C@H]([C@@H]([C@@H]1O)O)c1c[nH]c2c1ncnc2N
Isomeric SMILES c1c(c2c([nH]1)c(ncn2)N)[C@H]1[C@@H]([C@@H]([C@H](N1)CO)O)O
InChI InChI=1S/C11H15N5O3/c12-11-8-6(14-3-15-11)4(1-13-8)7-10(19)9(18)5(2-17)16-7/h1,3,5,7,9-10,13,16-19H,2H2,(H2,12,14,15)/t5-,7+,9-,10+/m1/s1
InChI Key AMFDITJFBUXZQN-KUBHLMPHSA-N
No information available.
Summary of Clinical Use Click here for help
A phase 1 study of galidesivir (BCX4430) in COVID-19 was terminated by the study sponsor (BioCryst Pharmaceuticals).
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02319772 A Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BCX4430 Phase 1 Interventional BioCryst Pharmaceuticals
NCT03800173 A Study to Evaluate the Single Dose Safety, Tolerability and Pharmacokinetics of IV BCX4430 Phase 1 Interventional BioCryst Pharmaceuticals
NCT03891420 A Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effects of Galidesivir in Yellow Fever or COVID-19 Phase 1 Interventional BioCryst Pharmaceuticals